Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 1
1993 2
1994 1
1995 1
1996 2
1997 3
1998 4
1999 5
2000 4
2001 3
2002 4
2003 4
2004 7
2005 4
2006 7
2007 5
2008 6
2009 14
2010 7
2011 7
2012 9
2013 10
2014 11
2015 7
2016 6
2017 11
2018 7
2019 6
2020 10
2021 5
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

163 results

Results by year

Filters applied: . Clear all
Page 1
Molecular origins of cancer: Molecular basis of colorectal cancer.
Markowitz SD, Bertagnolli MM. Markowitz SD, et al. Among authors: bertagnolli mm. N Engl J Med. 2009 Dec 17;361(25):2449-60. doi: 10.1056/NEJMra0804588. N Engl J Med. 2009. PMID: 20018966 Free PMC article. Review. No abstract available.
Rejoinder.
Bertagnolli MM, Anderson B, Quina A, Piantadosi S. Bertagnolli MM, et al. Clin Trials. 2020 Jun;17(3):251-252. doi: 10.1177/1740774520913848. Epub 2020 Apr 8. Clin Trials. 2020. PMID: 32266839 No abstract available.
VICTOR spoiled?
Goldberg RM, Bertagnolli MM. Goldberg RM, et al. Among authors: bertagnolli mm. J Clin Oncol. 2010 Oct 20;28(30):4546-8. doi: 10.1200/JCO.2010.31.6653. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837951 No abstract available.
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C. Venook AP, et al. Among authors: bertagnolli mm. JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105. JAMA. 2017. PMID: 28632865 Free PMC article. Clinical Trial.
Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).
Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O. Lenz HJ, et al. Among authors: bertagnolli mm. J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1. J Clin Oncol. 2019. PMID: 31042420 Free PMC article. Clinical Trial.
Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Basch E, et al. Among authors: bertagnolli mm. Clin Trials. 2021 Feb;18(1):104-114. doi: 10.1177/1740774520975120. Epub 2020 Dec 1. Clin Trials. 2021. PMID: 33258687 Free PMC article.
Linking Genotype to Phenotype: Bench to Bedside.
George S, Bertagnolli MM. George S, et al. Among authors: bertagnolli mm. Clin Cancer Res. 2022 Jul 1;28(13):2725-2727. doi: 10.1158/1078-0432.CCR-22-0027. Clin Cancer Res. 2022. PMID: 35467726
Accelerating anticancer drug development - opportunities and trade-offs.
Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL. Nass SJ, et al. Among authors: bertagnolli mm. Nat Rev Clin Oncol. 2018 Dec;15(12):777-786. doi: 10.1038/s41571-018-0102-3. Nat Rev Clin Oncol. 2018. PMID: 30275514 Review.
Concurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.
Schaefer IM, Hemming ML, Lundberg MZ, Serrata MP, Goldaracena I, Liu N, Yin P, Paulo JA, Gygi SP, George S, Morgan JA, Bertagnolli MM, Sicinska ET, Chu C, Zheng S, Mariño-Enríquez A, Hornick JL, Raut CP, Ou WB, Demetri GD, Saka SK, Fletcher JA. Schaefer IM, et al. Among authors: bertagnolli mm. Br J Cancer. 2022 Nov;127(11):2072-2085. doi: 10.1038/s41416-022-01990-5. Epub 2022 Sep 29. Br J Cancer. 2022. PMID: 36175617 Free PMC article.
163 results